Heidelberg Pharma AG/€HPHA
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Heidelberg Pharma AG
Heidelberg Pharma AG is a biotechnology company focused on developing novel cancer therapies. It specializes in a proprietary technology known as Antibody Targeted Amanitin Conjugates (ATACs), aimed at delivering potent toxins specifically to cancer cells. Founded in Germany, the company is headquartered in Ladenburg and operates primarily in the pharmaceutical sector, with a strong emphasis on research and development collaborations. Heidelberg Pharma positions itself by leveraging its unique ATAC platform, differentiating itself through targeted cancer treatment modalities. The company collaborates with pharmaceutical firms to enhance its development pipeline and commercial reach across various markets. Sources:
https://www.heidelberg-pharma.com/
Ticker
€HPHA
Sector
Primary listing
XETRA
Industry
Biotechnology
Headquarters
Employees
105
ISIN
DE000A11QVV0
Website
HPHA Metrics
BasicAdvanced
€213M
-
-€0.45
1.64
-
Price and volume
Market cap
€213M
Beta
1.64
52-week high
€5.36
52-week low
€2.11
Average daily volume
23K
Financial strength
Current ratio
7.149
Quick ratio
4.782
Long term debt to equity
0.144
Total debt to equity
0.606
Interest coverage (TTM)
-592.23%
Profitability
EBITDA (TTM)
-23.514
Gross margin (TTM)
73.80%
Net profit margin (TTM)
-303.90%
Operating margin (TTM)
-353.88%
Effective tax rate (TTM)
0.23%
Revenue per employee (TTM)
€70,000
Management effectiveness
Return on assets (TTM)
-26.48%
Return on equity (TTM)
-59.35%
Valuation
Price to revenue (TTM)
31.134
Price to book
8.48
Price to tangible book (TTM)
13.15
Price to free cash flow (TTM)
-7.625
Free cash flow yield (TTM)
-13.11%
Free cash flow per share (TTM)
-59.80%
Growth
Revenue change (TTM)
-24.29%
Earnings per share change (TTM)
12.29%
3-year revenue growth (CAGR)
44.14%
10-year revenue growth (CAGR)
4.61%
3-year earnings per share growth (CAGR)
-18.24%
10-year earnings per share growth (CAGR)
-1.16%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Heidelberg Pharma AG stock?
Heidelberg Pharma AG (HPHA) has a market cap of €213M as of July 04, 2025.
What is the P/E ratio for Heidelberg Pharma AG stock?
The price to earnings (P/E) ratio for Heidelberg Pharma AG (HPHA) stock is 0 as of July 04, 2025.
Does Heidelberg Pharma AG stock pay dividends?
No, Heidelberg Pharma AG (HPHA) stock does not pay dividends to its shareholders as of July 04, 2025.
When is the next Heidelberg Pharma AG dividend payment date?
Heidelberg Pharma AG (HPHA) stock does not pay dividends to its shareholders.
What is the beta indicator for Heidelberg Pharma AG?
Heidelberg Pharma AG (HPHA) has a beta rating of 1.64. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.